Document is current

Any future updates will be listed below

Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)

Crossref DOI link: https://doi.org/10.1007/s00415-025-12899-3

Published Online: 2025-02-17

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark